Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44. Following the completion of the sale, the senior vice president directly owned 202 shares in the company, valued at $61,096.92. This trade represents a 76.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total value of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The stock was sold at an average price of $257.63, for a total value of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.

BeOne Medicines Stock Performance

BeOne Medicines stock traded down $4.13 during mid-day trading on Friday, reaching $298.70. The company’s stock had a trading volume of 254,502 shares, compared to its average volume of 270,452. The company has a market capitalization of $32.77 billion, a P/E ratio of 66.82 and a beta of 0.49. The firm’s fifty day moving average price is $289.89 and its two-hundred day moving average price is $309.03. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $249.00 and a 12-month high of $385.22. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Guggenheim upped their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Barclays lifted their price objective on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Morgan Stanley reissued an “overweight” rating and set a $395.00 price objective on shares of BeOne Medicines in a research report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Finally, Royal Bank Of Canada increased their target price on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $391.38.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ONC. Capital International Investors raised its holdings in BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after acquiring an additional 67,808 shares during the last quarter. Siren L.L.C. raised its position in BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after buying an additional 7,010 shares during the last quarter. Morgan Stanley lifted its stake in BeOne Medicines by 23.9% during the 4th quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after acquiring an additional 84,367 shares during the period. Bank of America Corp DE lifted its stake in BeOne Medicines by 7.0% during the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after acquiring an additional 26,441 shares during the period. Finally, Candriam S.C.A. boosted its holdings in shares of BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after acquiring an additional 62,470 shares during the last quarter. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.